
  • Services
    • THERAPEUTIC AREAS
      • Epilepsy & Seizure Disorders
      • Mental Illness
      • Neurodegenerative Disorders
      • Neurodevelopmental Disorders
      • Neuromuscular Disorders
      • Pain Models
      • Rare CNS Disorders
      • Injury and Trauma
    • CAPABILITIES
      • Microdyalisis
      • Biomarker Analysis
      • Pharmacokinetics & Pharmacodynamics (PK/PD)
      • Target Engagement
      • Electrophysiology
  • In Vivo AI Platforms
    • eCube™
    • NeuroCube®
    • PhenoCube®
    • SmartCube®
  • News & Insights
    • News
      • Press Releases
      • Upcoming Events
    • Insights
      • Publications
      • Posters
      • Research Updates
  • About
    • Leadership Team
    • Corporate Citizenship
    • Culture
    • Careers
  • Contact Us

Male and female Fmr1 knockout mice on C57 albino background exhibit spatial learning and memory impairments.

by Desiree Cobb-Olori | Aug 29, 2010

Baker, K.; Wray, S.; Ritter, R.; Mason, S.; Lanthorn, T.; Savelieva, K. Genes, Brain and Behavior 2010, 9, 562-574.

The Novel triple reuptake inhibitor JZAD-IV-22 exhibits an Antidepressant Pharmacological profile without Locomotor Stimulant or Sensitization Properties.

by Desiree Cobb-Olori | Jun 29, 2010

Caldarone, B. J.; Paterson, N. E.; Zhou, J.; Brunner, D.; Kozikowski, A. P.; Westphal, K. G.; Korte-Bouws, G. A.; Prins, J.; Korte, S. M.; Olivier, B.; Ghavami, A J Pharmacol Exp Ther 2010, 335, 762-70.

Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents.

by Desiree Cobb-Olori | Jun 27, 2010

Paterson, N. E.; Fedolak, A.; Olivier, B.; Hanania, T.; Ghavami, A.; Caldarone, B. Pharmacol Biochem Behav 2010, 95, 449-56.

The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats.

by Desiree Cobb-Olori | Jun 25, 2010

Paterson, N. E.; Min, W.; Hackett, A.; Lowe, D.; Hanania, T.; Caldarone, B.; Ghavami, A. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34, 1455-64.

Comprehensive behavioral testing in the R6/2 mouse model of Huntington’s disease shows no benefit from CoQ10 or minocycline.

by Desiree Cobb-Olori | May 29, 2010

Menalled, L. B.; Patry, M.; Ragland, N.; Lowden, P. A.; Goodman, J.; Minnich, J.; Zahasky, B.; Park, L.; Leeds, J.; Howland, D.; Signer, E.; Tobin, A. J.; Brunner, D. PLoS One 2010, 5, e9793.
« Older Entries
Next Entries »
  • Therapeutic Areas
    • Epilepsy & Seizure Disorders
      • Preclinical Seizure Models
        • Chemical Induction Models
        • Electroshock-Induced Seizures
        • Amygdala-Induced Kindling
        • Harmaline-Induced Tremors
      • Dravet Syndrome
      • EEG Seizure
      • Angelman Syndrome
      • Rett Syndrome
      • Tuberous Sclerosis
    • Mental Illness
      • Anxiety
      • Depression
      • Schizophrenia
      • ADHD
      • Drug Abuse Liability
    • Neurodegenerative Disorders
      • Alzheimer’s Disease
      • Amyotrophic Lateral Sclerosis
      • Huntington’s Disease
      • Parkinson’s Disease
      • Spinal Muscular Atrophy (SMA)
    • Neurodevelopmental Disorders
      • ADHD Studies
      • Angelman Syndrome
      • Autism Spectrum Disorder
      • Fragile X Syndrome
      • Rett Syndrome
    • Neuromuscular Disorders
      • Amyotrophic Lateral Sclerosis
      • Charcot Marie Tooth Disease
      • Duchenne Muscular Dystrophy
      • Spinal Muscular Atrophy (SMA)
    • Pain Models
      • Acute Pain
      • Inflammatory Pain
      • Neuropathic Pain -Nerve Ligation
      • Osteoarthritis Pain Studies
      • Postoperative Pain Studies
      • PSPP Program
      • Visceral Pain
    • Rare CNS Disorders
      • Angelman Syndrome
      • Charcot Marie Tooth Disease
      • Dravet Syndrome
      • Fragile X Syndrome
      • Gaucher Disease
      • Rett Syndrome
      • Tuberous Sclerosis (TSC) Preclinical Research
    • Injury and Trauma
      • Spinal Cord Injury
      • Traumatic Brain Injury
  • Capabilities
    • Microdyalisis
    • Biomarker Analysis
      • Immunohistochemistry
      • Molecular Pharmacology
    • Pharmacokinetics & Pharmacodynamics (PK/PD)
    • Target Engagement
      • Receptor Occupancy
    • Electrophysiology
      • In vivo electrophysiology
      • Ex vivo electrophysiology
      • Compound Muscle Action Potention

Let’s Find the Right Solution Together

Our scientists are here to help you find the right model or capability for your program.

Request a Consultation

Quick Links

  • Services
  • In Vivo AI Platforms
  • News & Insights
  • About
  • Contact

Contact

Address

215 College Road
Paramus, NJ 07652

Email

info@psychogenics.com

Phone

(914) 406-8019

Fax

(914) 406-8090

© 2026 PsychoGenics Inc. All rights reserved.

  • Privacy Policy
  • Terms of Use
  • Financial Conflict of Interest Policy
  • Sitemap
  • Webmaster
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}